OTR Therapeutics has emerged from stealth with the closing of a $100 million Series A financing that strengthens the company’s strategy to advance early scientific innovation into globally deployable therapies. The funding round, completed in June 2025, was backed by True Light Capital, LAV, Pfizer Ventures, and Sirona Capital.Read More
OTR Therapeutics: $100 Million Series A Raised To Accelerate Global Drug Development
